
    
      This is a single arm, open-label, single-center study. This study is indicated for CD 70 CAR
      T for patients with CD70 positive malignant hematologic diseases. The selections of dose
      levels and the number of subjects are based on clinical trials of similar foreign products.
      108 patients will be enrolled. Primary objective is to explore the safety,main consideration
      is dose-related safety.
    
  